Compare VIRT & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VIRT | BLCO |
|---|---|---|
| Founded | 2008 | 1853 |
| Country | United States | Canada |
| Employees | 1027 | N/A |
| Industry | Investment Bankers/Brokers/Service | Ophthalmic Goods |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.4B |
| IPO Year | 2014 | 2022 |
| Metric | VIRT | BLCO |
|---|---|---|
| Price | $68.72 | $17.24 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $45.60 | $18.45 |
| AVG Volume (30 Days) | ★ 1.3M | 403.6K |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.89% | N/A |
| EPS Growth | ★ 72.73 | N/A |
| EPS | ★ 3.62 | N/A |
| Revenue | $3,632,118,000.00 | ★ $5,101,000,000.00 |
| Revenue This Year | N/A | $8.65 |
| Revenue Next Year | $1.34 | $5.59 |
| P/E Ratio | $16.90 | ★ N/A |
| Revenue Growth | ★ 26.25 | 6.47 |
| 52 Week Low | $31.55 | $13.77 |
| 52 Week High | $68.02 | $18.92 |
| Indicator | VIRT | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 69.40 | 60.83 |
| Support Level | $55.11 | $16.26 |
| Resistance Level | N/A | $17.36 |
| Average True Range (ATR) | 3.13 | 0.43 |
| MACD | 0.94 | 0.04 |
| Stochastic Oscillator | 93.92 | 70.68 |
Virtu Financial Inc is a financial firm that leverages technology to deliver liquidity to the world-wide markets and transparent trading solutions to its clients. The company's operating segment includes Market Making; and Execution Services. The non-operating segment of the company includes the Corporate segment. The company generates maximum revenue from the market-making segment. The Market Making segment principally consists of market-making in the cash, futures, and options markets across equities, options, fixed income, currencies, and commodities. Geographically, it derives a majority of its revenue from the United States and also has a presence in Ireland and Other Countries.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.